ArticleJournal of ovarian research2025
Oxidoreductase delivery by cell therapies in cyclophosphamide-induced premature ovarian insufficiency: a mechanistic insight into ovarian rejuvenation.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe etiologically diverse decline in ovarian function among females represents a significant contributor to the rising incidence of infertility. Recent advances in cell-based therapies, including mesenchymal stem cells (MSCs) and autologous stromal vascular fraction (SVF), has shown potential in rejuvenating ovarian function. Yet, the efficacy heterogeneity and mechanisms of action warrant further investigation for validation.
methodsThis study investigates the therapeutic efficacy of human umbilical cord-derived MSCs (HucMSCs), adipose tissue-derived MSCs (ADSCs), and stromal vascular fraction (SVF) in a cyclophosphamide (CTX)-induced premature ovarian insufficiency (POI) mouse model. Equivalent doses of these cells were orthotopically administered, and their impact on ovarian function was meticulously evaluated using comprehensive functional and histological assays. RNA sequencing and proteomic analysis were employed to elucidate the underlying mechanisms.
resultsOur findings reveal that HucMSCs, ADSCs, and SVF robustly enhance follicle development, hormonal balance, oocyte quality, and embryonic developmental potential, leading to improved fertility outcomes. In vitro co-culture with granulosa cells (GCs) demonstrated that all three cell types significantly promoted GC proliferation. Proteomic evaluation identified oxidoreductase enzymes as key players in mitigating ovarian injury by alleviating oxidative stress within oocytes and GCs.
conclusionsThese results underscore the therapeutic potential of HucMSCs, ADSCs, and SVF in rejuvenating ovarian function and highlight their promise as versatile and effective cell-based therapies for clinical application in female infertility. This study provides critical insights and a foundation for advancing the clinical translation of these cell-based materials as promising agents for female infertility, offering new hope for women facing ovarian dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.